Media
Follow our progress and stay up to date with our press releases and media coverage.
Press Releases
GeneVentiv Welcomes New Scientific Advisory Board Member, Sylvia Fong
July 23, 2024 Damon R. Race, President & CEO RALEIGH, NC – GeneVentiv Therapeutics, a pre-clinical gene therapy company focused on blood diseases and disorders, today announced that Sylvia Fong, Ph.D. has joined the Company’s Scientific Advisory Board as the...
ReciBioPharm and GeneVentiv Therapeutics partner to advance first AAV-based gene therapy for haemophilia patients with inhibitors
March 13 2024 ReciBioPharm, the advanced and emerging therapies business unit of Recipharm, has announced a collaboration agreement with GeneVentiv Therapeutics, a pre-clinical gene therapy company, to advance development of an Adeno-Associated Virus (AAV)-based...
GeneVentiv to Attend BIO CEO & Investor Conference
January 30, 2024 Damon R. Race, President & CEO RALEIGH, NC – GeneVentiv Therapeutics, a pre-clinical gene therapy company focused on blood disorders, today announced it will attend the BIO CEO & Investor Conference, which will be held in New York, NY from...
GeneVentiv to Attend Biotech Showcase
November 30, 2023 Damon R. Race, President & CEO RALEIGH, NC – GeneVentiv Therapeutics, a pre-clinical gene therapy company focused on blood disorders, today announced it will attend the Biotech Showcase and BIO Partnering meetings during the J.P. Morgan...
GeneVentiv Therapeutics to Attend BIO Europe Fall 2023
October 10, 2023 Damon R. Race, President & CEO RALEIGH, NC – GeneVentiv Therapeutics, a pre-clinical gene therapy company focused on blood disorders, today announced it will attend BIO Europe Fall 2023, which will be held from November 14-15, 2023. GeneVentiv...
GeneVentiv to Attend BIO Investor Forum
October 2, 2023 Damon R. Race, President & CEO RALEIGH, NC – GeneVentiv Therapeutics, a pre-clinical gene therapy company focused on blood disorders, today announced it will attend BIO Investor Forum, which will be held in San Francisco, CA from October 17-18,...
In the News
GeneVentiv Therapeutics Awarded $2.5 Million SBIR Grant to Advance Gene Therapy for All Hemophilias, with or without Inhibitors
Damon R. Race, President & CEO RALEIGH, N.C., April 16, 2024 /PRNewswire/ -- GeneVentiv Therapeutics, developer of GENV-HEM (AAV8.FVa) for all hemophilias, announced today it has been awarded a Direct to Phase II Small Business Innovation Research (SBIR) grant for...
New partners to develop universal gene therapy for hemophilia
ReciBioPharm, GeneVentiv to advance GENV-HEM to Phase 1/2 clinical testing by Margarida Maia, PhD | March 15, 2024 ReciBioPharm and GeneVentiv Therapeutics are teaming up to advance the development of GENV-HEM, a gene therapy for all hemophilia patients, including...
Rare Disease Advisor – An Interview with Damon Race, President and CEO of GeneVentiv Therapeutics
Larry Luxner, senior correspondent for Rare Disease Advisor, interviews Damon Race, CEO of GeneVentiv Therapeutics. The North Carolina-based startup hopes to develop a universal gene therapy that will benefit patients with hemophilia A or B with or without...
UNC-Chapel Hill gene therapy spinout raises $1.4 million
By Zac Ezzone – Staff writer, Triangle Business Journal Sep 1, 2022 A UNC-Chapel Hill spinout developing gene therapies focused on rare blood diseases and disorders has raised $1.4 million to support its efforts. The company, GeneVentiv Therapeutics, raised the...
Bootstrapped UNC spinout lands $300K for gene therapy work
The Old Well on the UNC-Chapel Hill campus. Mehmet Demirci By Zac Ezzone - Staff writer June 14, 2022, 08:52am EDT After bootstrapping for nearly two years, the CEO of a UNC-Chapel Hill spinout developing gene therapies has received some financial support. In March,...
Triangle gene therapy startup GeneVentiv Therapeutics awarded $250K loan from NC Biotech Center
Pixabay image by Jason Parker — June 8, 2022 RALEIGH – GeneVentiv Therapeutics, a Triangle-area pre-clinical gene therapy company, has been awarded a $250,000 Strategic Research Loan (SRL) from the North Carolina Biotechnology Center (NCBC). The loan will enable the...
GeneVentiv Therapeutics Wins KickStart Commercialization Grant
Shar March 16, 2022 By Shellie Edge KickStart Venture Services – the premier life sciences startup program and accelerator from Innovate Carolina – has awarded commercialization grants to two UNC-affiliated startup companies, Elipsys, LLC, and GeneVentiv Therapeutics,...
GeneVentiv Therapeutics selected to pitch at CED’s Venture Connect
https://wraltechwire.com/2022/03/07/startup-spotlight-presenting-companies-to-pitch-at-ceds-venture-connect/
Startup Spotlight: UNC-linked startup is giving hope to those with hemophilia
by Shellie Edge, Innovate Carolina — February 8, 2022 . Editor’s note: Startup Spotlight is a regular weekly feature in WRAL TechWire. This week’s feature comes from UNC-Chapel Hill’s Innovate Carolina. +++ CHAPEL HILL – For most people, a small cut on the hand or...